SCHEDULE: Yorkville Advisors Discloses 9.9% Stake in TransCode

Yorkville Advisors and affiliates have reported a 9.9% beneficial ownership stake in TransCode Therapeutics following a convertible note purchase.

Summary

• YA II PN, Ltd. and affiliated entities have acquired a 9.9% beneficial ownership stake in TransCode Therapeutics, Inc.
• The stake consists of 101,772 shares of common stock.
• The acquisition follows a Standby Equity Purchase Agreement and the purchase of a convertible promissory note on April 15, 2026.
• The reporting persons are prohibited from exceeding 9.99% ownership of the issuer's outstanding common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure of institutional ownership resulting from standard financing activities.

Positives

• The investment indicates institutional interest and capital support for the issuer's operations.

Negatives

• The issuance of convertible notes often leads to potential future dilution for existing shareholders upon conversion.

Risks

• The 9.99% ownership cap limits the ability of the reporting person to increase their stake without further disclosure or regulatory considerations.
• Potential for future equity dilution as the convertible note is converted into common stock.

Future Outlook

The reporting persons intend to hold the securities for investment purposes and do not currently seek to change or influence the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects a common financing structure for small-cap biotechnology firms, where institutional investors provide liquidity through convertible instruments, often resulting in incremental dilution.

Comparison to Industry Standards

• The use of Standby Equity Purchase Agreements is a standard mechanism for small-cap biotech companies to manage cash flow requirements.
• The 9.99% ownership blocker is a standard protective provision in institutional investment agreements to avoid triggering certain regulatory thresholds.

Stakeholder Impact

• Existing shareholders may experience dilution if the convertible note is converted into common stock.

Next Steps

• Potential conversion of the promissory note into common stock by the reporting person.
• Potential future acquisitions of common stock under the Purchase Agreement, subject to the 9.99% ownership cap.

Key Dates

Keywords

TransCode Therapeutics, Yorkville Advisors, Schedule 13G, Convertible Note, Equity Financing, Beneficial Ownership